A Shift in Adult Constipation Treatment: How PEG 3350 is Redefining Care

Brought to you by MuOUT^®

Constipation Care: Why Are Patients Still Struggling?

43% of patients report dissatisfaction with treatment.²

70% of patients require ≥2 medications over a period of 6 months.³

PEG-3350: The Answer to Better Outcomes With Patient Satisfaction

1	100% patient satisfaction: Complete evacuation and satisfactory relief were reported by all patients treated with PEG for their second BM (Figure 1).⁴

Figure 1. Efficacy of PEG-3350 in achieving satisfactory and complete BMs.

2	Faster symptom relief: The average time to first BM with PEG was 14.8 hours.⁴

3	Faster increase in BM frequency: By week 2, PEG resulted in an average of 4.5 BMs/week.^5*

4	Reduces polypharmacy: PEG consistently showed superior results in reducing the need for additional products compared to lactulose (Figure 2).⁶

Figure 2. Proportion of patients requiring no additional products.

Conclusion
From faster relief to fewer additional medications, PEG-3350 addresses dissatisfaction and simplifies treatment for chronic constipation patients.^4–6

Do you believe that the increased awareness around PEG 3350 has influenced your prescribing habits for adult constipation management?

Strongly influenced

Somewhat influenced

Not influenced

Not aware of the increased noise

*As compared to placebo.

Abbreviations ▼

BM: Bowel movement; PEG: Polyethylene glycol.

References ▼

1. Pashankar DS, et. al. Safety of polyethylene glycol 3350 for the treatment of chronic constipation in children, Arch Pediatr Adolesc Med. 2003;157(7):661–664. 2. Basilisco G; Italian Society of Neurogastroenterology Motility (SINGEM) Study Group. Patient dissatisfaction with medical therapy for chronic constipation or irritable bowel syndrome with constipation: analysis of N-of-1 prospective trials in 81 patients. Aliment Pharmacol Ther. 2020;51(6):629–636. 3. Stephenson JSM, Buono J, Spalding W, et al. Unmet treatment needs among commercially insured patients with irritable bowel syndrome with constipation (IBS-C) or chronic constipation (CC) in the U.S: 2216. Am J Gastroenterol. 2014;109(Suppl). 4. Di Palma JA, Smith JR, Cleveland Mv. Overnight efficacy of polyethylene glycol laxative. Am J Gastroenterol. 2002;97(7):1776–1779. 5. DiPalma JA, DeRidder PH, Orlando RC, et al. A randomized, placebo-controlled, multicenter study of the safety and efficacy of a new polyethylene glycol laxative. Am J Gastroenterol. 2000;95(2):446–450. 6. Lee-Robichaud H, Thomas K, Morgan J, et al. Lactulose versus polyethylene glycol for chronic constipation. Cochrane Database Syst Rev. 2010;(7):CD007570.

LMRC Code: GGI-CO-A1-AQS-300024228-ELC-L24-0095

Disclaimer: For the use of a Registered Medical Practitioner, Hospital or Laboratory only.

The images are for illustrative representation only and do not depict actual medical products, procedures, or outcomes. Refer to official medical guidance and product information for accurate details.

All content including: text, images, audio, or other formats were created for medical educational purposes only. Offerings for continuing education are clearly identified and the appropriate target audience is identified. This communication is restricted for the use of HCPs and must not be shared in public domain. The opinions expressed in this video are solely the views of the speaker. The presentation may contain off label usage of drug(s) aimed at educational purpose only. Dr. Reddy’s Laboratories Ltd including but not limited its Affiliates strictly does not recommend any off label usage of its marketing products. Prior to treatment kindly refer to the latest prescribing information approved by the local authorities. No part of this content may be used, reproduced, transmitted or stored in any form without the written permission of Dr. Reddy’s.

Pediatric functional constipation